

Registered Office:

Plot No. PF21 & PF-22/A, Charal Industrial Estate,
Sanand GIDC-II, Sanand,
Ahmedabad- 382110, Gujarat.

CIN.: L24230GJ2015PLC085451

Date: November 12, 2025

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra East, Mumbai-400051

Dear Sir/Ma'am,

Sub: Outcome of board meeting held today i.e. on Wednesday, November 12, 2025, in terms of second proviso to Regulation 30(6) Of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Sotac Pharmaceuticals Limited (SYMBOL / ISIN: SOTAC/ INE002D01012)

In reference to captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held today, i.e. on Wednesday, November 12, 2025, at the Registered Office of the Company situated at Plot No. PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Sanand, Ahmedabad, 382110 Gujarat, India, has inter-alia;

1. Considered and approved the Unaudited Standalone & Consolidated Financial Results of the Company for the half year ended on September 30, 2025, along with Statement of Assets and Liabilities and Cash Flow Statement as per provisions of Regulation 33 of the SEBI Listing Regulations, along with Limited Review Report;
2. Considered and approved all other business as per agenda circulated.

The meeting of Board of Directors of the Company commenced at 4:00 PM (IST) and concluded at 5:00 PM (IST).

Kindly take the same on your records and oblige us.

Thanking you.

Yours faithfully,

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252

Place: Ahmedabad

SOTAC PHARMACEUTICALS LIMITED



Registered Office:

Plot No. PF21 & PF-22/A, Charal Industrial Estate,
Sanand GIDC-II, Sanand,
Ahmedabad- 382110, Gujarat.

CIN.: L24230GJ2015PLC085451

Date: November 12, 2025

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra East, Mumbai-400051

Dear Sir/Ma'am,

Sub: Submission of Unaudited Standalone & Consolidated Financial Results of the Company for the half year ended on September 30, 2025 along with Limited Review Report.

Ref: Sotac Pharmaceuticals Limited (SYMBOL / ISIN: SOTAC/ INE002D01012)

With reference to captioned subject and pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Unaudited Standalone and Consolidated Financial Results of the Company for the half year ended on 30th September, 2025, along with Limited Review Report issued by Statutory Auditors for the half year ended on 30th September, 2025.

Kindly take the same on your records and oblige us.

Thanking You.

Yours faithfully,

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252

Place: Ahmedabad

End: A/a-

Contact No.: 99135 62852, 87994 83159, 99250 45971



www.sotacpharma.com



sotacpharma@gmail.com



Auditor's Limited Review Report on unaudited Consolidated Financial results of Sotac Pharmaceutical Limited, for the Half Year ended September 30, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors of,
Sotac Pharmaceutical Limited

We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of **Sotac Pharmaceutical Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the half year ended September 30, 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

1. Sotac Pharmaceutical Limited ("Parent")
2. Sotac Healthcare Private Limited ("Subsidiary")
3. Sotac Lifesciences Private Limited ("Subsidiary")
4. Sotac Research Private Limited ("Subsidiary")

Based on our review conducted and procedures performed as stated in above and based on the statement provided by the Management related to parent & subsidiary, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the




recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the interim financial statements / financial information / financial results of Subsidiaries i.e. "Sotac Healthcare Private Limited" ("Subsidiary"), "Sotac Lifesciences Private Limited" ("Subsidiary") and Sotac Research Private Limited ("Subsidiary") included in the consolidated unaudited financial results, whose interim financial statements / financial information / financial results reflect total revenues of Rs.1296.49 Lakhs, total net profit/(loss) after tax of Rs.25.68 Lakhs and net cash flow of RS. 83.23 Lakhs for the half year ended September 30, 2025, respectively, as considered in the consolidated unaudited financial results, whose interim financial statements / financial information/ financial results have not been reviewed by us. These interim financial statements / financial information / financial results have been provided by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary is based solely on the reports of the Management and the procedures performed by us as stated in above.

Our conclusion on the statement is not modified in respect of the above matters.

For, Keyur Shah & Co.
Chartered Accountants
F.R.No. 141173W




Keyur B. Shah
Proprietor
M No. 153774
UDIN: -25153774BMIOXX9719

Date: - 12/11/2025
Place: Ahmedabad

SOTAC PHARMACEUTICALS LIMITED
CIN:U24230GJ2015PLC085451
Plot No PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110
Unaudited Consolidated Financial Result for the half year ended 30th September, '25

(INR in lakhs unless otherwise stated)

Sr no.	Particulars	Half Year ended		Year ended	
		30th September, '25	31st March, '25	30th September, '24	31st March, '25
		Unaudited	Audited	Unaudited	Audited
I)	Revenue From Operations	3,701.05	4,439.18	5,259.47	9,698.65
II)	Other Income	428.69	319.63	70.05	389.68
III)	Total Income (I + II)	4,129.74	4,758.81	5,329.52	10,088.33
IV)	Expenses				
a)	Cost of Material Consumed	2,445.83	2,448.37	3,844.25	6,292.62
b)	Purchase of Stock-in-Trade	70.23	61.45	71.76	133.21
c)	Changes in Inventories of Finished Goods/ Work-In-Progress/ Stock in Trade	(105.47)	186.53	218.68	405.21
d)	Employee Benefit Expenses	216.89	154.32	163.03	317.35
e)	Finance Costs	187.70	156.51	101.44	257.95
f)	Depreciation and Amortisation Expense	269.96	235.07	148.45	383.52
g)	Other Expenses	709.20	656.68	529.79	1,186.47
	Total Expenses (IV)	3,794.34	3,898.93	5,077.40	8,976.33
V)	Profit/(Loss) Before Exceptional & Extraordinary Items & Tax (III - IV)	335.40	859.88	252.12	1,112.00
VI)	Exceptional/Prior Period Items	(0.22)	-	(0.04)	(0.04)
	Profit/(loss) from ordinary activities before Extraordinary Items and Tax (V- VI)	335.18	859.88	252.08	1,111.96
VII)	Extraordinary Items	-	-	-	-
IX)	Profit Before Tax (VII-VIII)	335.18	859.88	252.08	1,111.96
X)	Tax Expense				
a)	Current Tax	83.94	94.04	77.81	171.85
b)	Deferred Tax	(7.67)	15.16	(2.58)	12.58
c)	Income Tax Prior Period	-	-	-	-
	Total Tax Expenses (X)	76.27	109.20	75.23	184.43
XI)	Profit (Loss) for the period from continuing operations (IX-X)	258.91	750.68	176.85	927.53
XII)	Profit/(loss) from discontinuing operations	-	-	-	-
XIII)	Tax expense of discontinuing operations	-	-	-	-
XIV)	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	-	-	-	-
XV)	Profit / (Loss) For The Period/Year before Minorities (XI+XIV)	258.91	750.68	176.85	927.53
XVI)	Less: Share of Minorities In Subsidiary Companies (Loss)/Profit	14.32	139.27	(14.40)	124.87
XVII)	Profit/(Loss) for the period	244.59	611.41	191.25	802.66
XVIII)	Paidup Equity Share Capital (Face value Rs 10 each)	1,105.00	1,105.00	1,105.00	1,105.00
XIX)	Reserve & Surplus (Excluding Revaluation Reserve)				4,220.19
XX)	Earnings Per Equity Share-Basic/Diluted				
	Basic /Diluted earnings per share (In INR)	2.21	5.53	1.73	7.26
	(not annualised, for the Half year ended)				



SOTAC PHARMACEUTICALS LIMITED
CIN:L24230GJ2015PLC085451
Plot No PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110
Unaudited Consolidated Financial Result for the half year ended 30th September,'25

Notes:

- [1] The consolidated unaudited financial results are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable
- [2] The above consolidated audited financial results for the half year and year ended 30th September, '25 have been prepared by the Company in accordance with Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on 12th November, '25.
- [3] As per MCA Notification dated 16th February, 2015 Companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2009, are exempted from the compulsory requirement of adoption of IND-AS.
- [4] The figures for the half year ended 30th September, '25 are the Balancing figures between the unaudited figures in respect of full financial year and unaudited figures in respect of first half of the financial year 24-25.
- [5] The figures of the previous period have been re-grouped / rearranged and / or recasted wherever considered necessary.
- [6] Company is mainly engaged in manufacturing of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta-lactam Syrup and external preparations looking into the nature of business company is operating under single segment hence segment reporting is not applicable to Company.
- [7] The Status of investor's complaints during the half year ended on 30th September, '25 as under:-

Complaints pending at the beginning of the period	Nil
Complaints received during the period	Nil
Complaints disposed during the period	Nil
Complaints resolved at the end of the period	Nil

[8] **List of the Entities Consolidated in the Statement:**

Name of the Subsidiaries Companies	% of Holding as on 30th September, '25	Relationship	Voting Power Either Directly or Indirectly through Subsidiaries
Sotac Healthcare Private Limited	71.00	Subsidiary	Directly
Sotac Research Private Limited	100.00	Subsidiary	Directly
Sotac Lifesciences Private Limited	55.77	Subsidiary	Directly

Place : Ahmedabad
Date : 12th November, '25



For & on behalf on Sotac Pharmaceuticals Limited


(Signature)

Sharad Patel
DIN:07252252
Chairman & Managing Director

SOTAC PHARMACEUTICALS LIMITED
CIN:L24230GJ2015PLC085451
Plot No PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110
Unaudited Consolidated Balance Sheet As At 30th September, '25

Particulars	(Amount in Lakhs)	
	As at	As at
	30th September, '25 Unaudited	31st March, '25 Audited
I. EQUITY AND LIABILITIES		
Share Holder's Fund		
(a) Share Capital	1,105.00	1,105.00
(b) Reserves and Surplus	4,463.12	4,220.19
	5,568.12	5,325.19
Share Application Money Pending Allotment	-	-
Minority Interest	531.36	517.04
Non-Current Liabilities		
(a) Long-Term Borrowings	940.89	1,419.41
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long Term Liabilities	-	-
(d) Long Term Provisions	16.52	16.28
Total Non-Current Liabilities	957.41	1,435.69
Current Liabilities		
(a) Short-Term Borrowings	2,883.37	2,950.52
(b) Trade Payable		
i) Total outstanding dues of micro enterprise and small enterprise	1,291.42	666.99
ii) Total outstanding dues other than micro enterprise and small enterprise	787.41	1,227.44
(c) Other Current Liabilities	152.84	156.20
(d) Short-Term Provisions	155.02	153.75
Total Current Liabilities	5,270.06	5,154.90
TOTAL EQUITY & LIABILITIES	12,326.95	12,432.82
II. ASSETS		
Non-Current Assets		
(a) Property, Plant & Equipment & Intangible Assets		
(i) Property, Plant & Equipment	4,540.77	4,676.77
(ii) Intangible Assets	1.57	1.85
(iii) Capital work In -Progress	81.23	20.35
(iv) Goodwill on Consolidation	190.34	190.34
(b) Non-Current Investments	267.66	378.19
(c) Deferred Tax Assets (Net)	137.75	130.09
(d) Long Term Loans and Advances	52.52	52.49
Total Non-Current Assets	5,271.84	5,450.08
Current Assets		
(a) Current investments	-	-
(b) Inventories	1,923.64	2,026.09
(c) Trade Receivables	3,274.35	3,411.22
(d) Cash and Cash Equivalents	220.01	156.39
(e) Short-Term Loans And Advances	51.38	52.17
(f) Other Current Assets	1,585.73	1,336.87
Total Current Assets	7,055.11	6,982.74
TOTAL ASSETS	12,326.95	12,432.82

For, Sotac Pharmaceuticals Limited



Sharad Patel
DIN:07252252
Chairman & Managing Director

Place: Ahmedabad
Date : 12th November, '25



SOTAC PHARMACEUTICALS LIMITED

CIN:U24230GJ2015PLC085451

(Formerly known as Sotac Pharmaceuticals Private Limited)

Plot No PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110

Unaudited Consolidated Cash Flow Statement for the half year ended on 30th September, 2025

Particulars	(Amount in Lakhs)	
	For the Period ended	For the Period ended
	30th September, '25	30th September, '24
	Unaudited	Unaudited
Cash Flow from Operating Activities		
Net Profit before tax paid	335.18	252.08
Adjustments for :		
Depreciation and amortization	269.96	148.45
Interest income	(5.61)	(29.70)
Dividend Income	(0.65)	
Provision for Gratuity	2.06	2.50
Finance Cost	187.70	101.44
Effect of IPO Expense and Deffered Government Grants	(1.67)	(1.67)
Operating profit before working capital changes (A)	786.97	473.09
Adjustment for Changes in Working Capital :		
Increase / (Decrease) in Trade Payables	184.40	409.46
Increase / (Decrease) in Other Current Liabilities	(3.36)	73.50
Increase / (Decrease) in Short term Provisions	6.50	(0.07)
(Increase) / Decrease in Inventories	102.45	158.90
(Increase) / Decrease in Trade Receivables	136.88	(184.57)
(Increase) / Decrease in Short Term Loans and Advances	0.79	(84.02)
(Increase) / Decrease in Other Current Assets	(248.85)	(67.42)
Operating profit after working capital changes (B)	178.81	305.78
Cash generated from Operations (A + B)	965.78	778.87
Taxes paid (net of refund)	(91.01)	(18.35)
Net Cash generated from Operations (A)	874.77	760.52
Cash Flow from Investing Activities		
Addition in Property, Plant and Equipments and Intangible Assets	(134.47)	(518.09)
Disposals Of Property, Plant and Equipments And Intangible Assets	0.80	0.43
(Increase) / Decrease in Capital Work in Progress	(60.88)	(349.64)
(Increase) / Decrease in of Loans and advances	(0.03)	(0.78)
(Increase) / Decrease In Non Current Investments	110.54	(408.25)
Interest income	5.61	29.70
Dividend Income	0.65	
Net Cash generated / (used) in Investing Activities (B)	(77.78)	(1,246.63)



SOTAC PHARMACEUTICALS LIMITED**CIN:U24230GJ2015PLC085451****(Formerly known as Sotac Pharmaceuticals Private Limited)****Plot No PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110****Unaudited Consolidated Cash Flow Statement for the half year ended on 30th September, 2025**

Particulars	(Amount in Lakhs)	
	For the Period ended 30th September, '25	For the Period ended 30th September, '24
Cash Flow from Financing Activities		
Increase / (Decrease) In Minority Interest	-	(15.00)
Increase / (Decrease) in Long Term Borrowings	(478.52)	(72.63)
Increase / (Decrease) of Short term Borrowings	(67.15)	385.51
Finance Cost	(187.70)	(101.44)
Net Cash Used in Financing Activities (C)	(733.37)	196.45
Net Changes in Cash and Cash Equivalents (A + B + C)	63.62	(289.66)
Cash and Cash Equivalents beginning of the Period	156.39	341.78
Cash and Cash Equivalents ending of the Period	220.01	52.12

Notes :**As per our attached report of even date**

1. The above cashflow flow statement has been prepared under the indirect method set out in Accounting method set out in Accounting Standard-3, "Cash Flow Statement" notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules 2014.

Place: Ahmedabad

Date : 12th November, '25



For, Sotac Pharmaceuticals Limited

Sharad Patel
DIN:07252252
Chairman & Managing Director



Auditor's Limited Review Report on unaudited Standalone Financial results of Sotac Pharmaceutical Limited, for the Half year ended September 30, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors of,
Sotac Pharmaceutical Limited

We have reviewed the accompanying the statement of unaudited Standalone financial results of **Sotac Pharmaceutical Limited** for the half year ended September 30, 2025. The Financial Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this financial statement based on the review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the independent Auditor of the Entity", issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primary to inquire of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone financial results prepared in accordance with applicable standards and other recognized accounting practices and policies has not disclosed the information require to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Keyur Shah & Co.
Chartered Accountants
F.R.No. 141173W


Keyur Shah
Proprietor
M. No. 153774
UDIN: - 25153774BMIOXW1278



Date: - 12/11/2025
Place: - Ahmedabad

SOTAC PHARMACEUTICALS LIMITED


CIN:L24230GJ2015PLC085451

Plot No PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110

Unaudited Standalone Financial Result for the half year ended 30th September, '25

(INR in Lakhs unless otherwise Specified)

Sr no.	Particulars	Half year ended		Year ended	
		30th September, '25	31st March, '25	30th September, '24	31st March, '25
		Unaudited	Audited	Unaudited	Audited
I)	Revenue From Operations	2,480.32	3,177.00	3,061.42	6,238.42
II)	Other Income	109.99	145.25	92.25	237.50
III)	Total Income (I + II)	2,590.31	3,322.25	3,153.67	6,475.92
IV)	Expenses				
a)	Cost of Material Consumed	1,462.45	1,940.43	2,002.95	3,943.38
b)	Purchase of Stock-in-Trade	70.23	61.45	71.76	133.21
c)	Changes in Inventories of Finished Goods/ Work-In-Progress/ Stock in Trade	(66.46)	183.04	133.21	316.25
d)	Employee Benefit Expenses	112.02	78.97	97.97	176.94
e)	Finance Costs	101.38	67.13	49.58	116.71
f)	Depreciation and Amortisation Expense	121.12	127.42	119.98	247.40
g)	Other Expenses	476.97	506.64	393.94	900.58
	Total Expenses (IV)	2,277.71	2,965.08	2,869.39	5,834.47
V)	Profit/(Loss) Before Exceptional & Extraordinary Items & Tax (III - IV)	312.60	357.17	284.28	641.45
VI)	Exceptional/Prior Period Items	(0.22)	-	(0.04)	(0.04)
	Profit/(Loss) from ordinary activities Before Extraordinary Items & Tax (V-VI)	312.38	357.17	284.24	641.41
VII)	Extraordinary Items	-	-	-	-
IX)	Profit Before Tax (VII-VIII)	312.38	357.17	284.24	641.41
X)	Tax Expense				
a)	Current Tax	83.94	95.37	76.10	171.47
b)	Deferred Tax	(4.78)	(3.73)	(3.50)	(7.23)
c)	Income Tax Excess Provisions Related to Earlier Years	-	-	-	-
	Total Tax Expense	79.16	91.64	72.60	164.24
XI)	Profit (Loss) for the period from continuing operations (IX-X)	233.22	265.53	211.64	477.17
XII)	Profit/(loss) from discontinuing operations	-	-	-	-
XIII)	Tax expense of discontinuing operations	-	-	-	-
XIV)	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	-	-	-	-
XV)	Profit / (Loss) For The Period/Year (XI+XIV)	233.22	265.53	211.64	477.17
XVI)	Paid up Equity Share Capital (Face value Rs 10 each)	1105.00	1105.00	1105.00	1105.00
XVII)	Reserve & Surplus (Excluding Revaluation Reserve)				4197.94
XVIII)	Earnings Per Equity Share-Basic/Diluted				
	Basic /Diluted earnings per share (In INR) (not annualised, for the Half year ended)	2.11	2.40	1.92	4.32



SOTAC PHARMACEUTICALS LIMITED

CIN:L24230GJ2015PLC085451

Plot No PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110

Unaudited Standalone Financial Result for the half year ended 30th September, '25

Notes:

- [1] The above standalone Unaudited financial results for the Half Year Ended on 30th September, '25 have been prepared by the Company in accordance with regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the board of directors in their meeting held on 12th November, '25.
- [2] The standalone unaudited financial results are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable
- [3] As per MCA Notification dated 16th February, 2015 Companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2009, are exempted from the compulsory requirement of adoption of IND-AS.
- [4] The figures for the half year ended 31st March 2025 are the Balancing figures between the audited figures in respect of full financial year and unaudited figures in respect of first half of the financial year 2024-25.
- [5] Previous Year's /period's figures have been regrouped/rearranged/ restated/adjusted/rectified/recasted wherever considered necessary.
- [6] In accordance with regulation 33 of SEBI (LODR) Regulation 2015, the above results have been reviewed by the Statutory Auditors of the Company.
- [7] Company is mainly engaged in manufacturing of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta-lactam Syrup and external preparations looking into the nature of business company is operating under single segment, hence segment reporting is not applicable to
- [8] The Status of investor's complaints during the Half year ended on 30th September, '25 as under:-

Complaints pending at the beginning of the period	Nill
Complaints received during the period	Nill
Complaints disposed during the period	Nill
Complaints resolved at the end of the period	Nill

Place : Ahmedabad
Date : 12th November '25



For & on behalf of Sotac Pharmaceuticals Limited

Sharad Patel
Chairman & Managing Director
DIN:07252252

SOTAC PHARMACEUTICALS LIMITED

CIN:L24230GJ2015PLC085451

Plot No PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110

Unaudited Standalone Balance Sheet as at 30th September, '25

(INR in lakhs, unless otherwise stated)

Particulars	As at 30th September '25	As at 31st March '25
	Unaudited	Audited
I. EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	1,105.00	1,105.00
(b) Reserves And Surplus	4,430.34	4,197.94
(c) Money Received Against Share Warrants	-	-
	5,535.34	5,302.94
(2) Share Application Money Pending Allotment	-	-
(3) Non-Current Liabilities		
(a) Long-Term Borrowings	304.49	563.48
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long Term Liabilities	-	-
(d) Long Term Provisions	13.43	13.69
Total Non-Current Liabilities	317.92	577.17
(4) Current Liabilities		
(a) Short-Term Borrowings	1,285.27	1,449.30
(b) Trade Payable		
i) Total outstanding dues of micro enterprise and small enterprise	869.00	449.76
ii) Total outstanding dues other than micro enterprise and small enterprise	324.17	483.39
(c) Other Current Liabilities	139.66	145.51
(d) Short-Term Provisions	125.45	121.34
Total Current Liabilities	2,743.55	2,649.30
TOTAL EQUITY & LIABILITIES	8,596.81	8,529.41
II. ASSETS		
(1) Non-Current Assets		
(a) Property, Plant & Equipment & Intangible Assets		
(i) Property, Plant & Equipment	1,614.20	1,664.29
(ii) Intangible Assets	1.57	1.85
(iii) Capital Work In -Progress	81.23	20.35
(b) Non-Current Investments	1,222.86	1,333.40
(c) Deferred Tax Assets (Net)	24.64	19.85
Total Non-Current Assets	2,944.50	3,039.74
(2) Current Assets		
(a) Current investments	-	-
(b) Inventories	1,063.75	1,017.51
(c) Trade Receivables	2,313.49	2,468.09
(d) Cash and Cash Equivalents	25.01	44.61
(e) Short-Term Loans And Advances	1,268.89	1,232.58
(f) Other Current Assets	981.17	726.88
Total Current Assets	5,652.31	5,489.67
TOTAL ASSETS	8,596.81	8,529.41

For & on behalf of Sotac Pharmaceuticals Limited


Sharad Patel
Chairman & Managing Director
DIN:07252252



Place: Ahmedabad
Date : 12th November '25

SOTAC PHARMACEUTICALS LIMITED

CIN:L24230GJ2015PLC085451

Plot No PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110

Unaudited Standalone Cashflow Statement for the Half year ended as on 30th September '25

(Amount in Lakhs)

Particulars	For the Period ended 30th September'25	For the Period ended 30th September'24
	Unaudited	Unaudited
Cash Flow from Operating Activities		
Net Profit Before Tax Paid	312.38	284.24
Adjustments for :		
Depreciation And Amortization	121.12	119.98
Interest Income	(106.82)	(62.58)
Finance Cost	101.38	49.58
Provision for Gratuity	1.55	2.44
Adjustment Related to IPO Expense and Deffered Government Grants	(0.83)	(0.83)
Operating Profit Before Working Capital Changes (a)	428.78	392.83
Adjustment For Changes In Working Capital :		
Increase / (Decrease) In Trade Payables	260.02	486.45
Increase / (Decrease) In Other Current Liabilities	(5.85)	83.52
Increase / (Decrease) In Short term Provisions	17.66	(3.83)
(Increase) / Decrease In Inventories	(46.24)	136.84
(Increase) / Decrease In Trade Receivables	154.60	(123.71)
(Increase) / Decrease In Short Term Loans and Advances	(36.31)	(401.58)
(Increase) / Decrease In Other Current Assets	(254.29)	(84.06)
(b)	89.59	93.63
Cash Generated From Operations (a+b)	518.36	486.46
Taxes Paid (Net Of Refund)	(97.49)	(18.35)
Net Cash Generated From Operations (A)	420.88	468.11
Cash Flow From Investing Activities		
Addition In Property, Plant and Equipments And Intagible Assets	(70.75)	(51.76)
Disposals Of Property, Plant and Equipments And Intagible Assets	-	0.43
Addition In Capital Work In Progress	(60.88)	-
(Increase) / Decrease In Non Current Investment	110.54	(403.52)
Interest Income	106.82	62.58
Net Cash Generated / (Used) in Investing Activities (B)	85.73	(392.27)



SOTAC PHARMACEUTICALS LIMITED

CIN:L24230GJ2015PLC085451

Plot No PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110

Unaudited Standalone Cashflow Statement for the Half year ended as on 30th September '25

(Amount in Lakhs)

Particulars	For the Period ended 30th September'25	For the Period ended 30th September'24
	Unaudited	Unaudited
Cash Flow From Financing Activities		
Proceeds From Issue of Equity Share	-	-
Proceeds From Securities Premium	-	-
Proceeds From Share Application Money Received	-	-
Repayment of Long Term Borrowings	(258.99)	(64.59)
Proceeds From Long Term Borrowings	-	-
Increase / (Decrease) In of Short term Borrowings	(164.03)	(2.47)
Increase / (Decrease) In long term Provisions	(1.81)	-
Finance Cost	(101.38)	(49.58)
Net Cash Used In Financing Activities (C)	(526.21)	(116.64)
Net Increase In Cash And Cash Equivalents (A+B+C)	(19.60)	(40.81)
Cash And Cash Equivalents As On 01st April '25	44.61	64.17
Cash And Cash Equivalents As On 30th September '25	25.01	23.36

Notes :

The above Cash flow statement has been prepared under the indirect method set out in Accounting Standard-3, "Cash Flow Statement" notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules 2014.

Place: Ahmedabad
Date : 12th November '25



For & on behalf of Sotac Pharmaceuticals Limited

Sharad Patel
Chairman & Managing Director
DIN:07252252